New treatment approach for acute myeloid leukemia with mutant RUNX1
Novel combination therapy for AML expressing mutant RUNX1
This study is looking at a new treatment approach for adults with acute myeloid leukemia who have a specific gene mutation that makes their condition harder to treat, and it aims to find better ways to help these patients respond to therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10910910 on NIH RePORTER |
What this research studies
This research focuses on developing a novel combination therapy for adult patients with acute myeloid leukemia (AML) that express mutant RUNX1, a gene associated with poor treatment outcomes. The study aims to understand how these mutations affect the disease and to identify effective targeted therapies. By utilizing advanced techniques like RNA sequencing and connectivity mapping, researchers are exploring the potential of specific drugs that could improve treatment efficacy for patients with this genetic mutation. The goal is to enhance the effectiveness of existing therapies and provide better outcomes for those affected by AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who have mutations in the RUNX1 gene.
Not a fit: Patients without RUNX1 mutations or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with AML, particularly those with the challenging mutant RUNX1.
How similar studies have performed: Other research has shown promise in targeting genetic mutations in leukemia, suggesting that this approach could be effective, although the specific combination therapy being tested is novel.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Dinardo, Courtney — University of Tx Md Anderson Can Ctr
- Study coordinator: Dinardo, Courtney
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.